The existence of the alternative Nogo‐B/integrin pathway might provide another plausible explanation for the recurrence of many types of tumors after anti‐VEGF therapy as well as represents an attractive target for the development of new effective therapeutics against tumor angiogenesis. This evidence concerns the gene RTN4 and neoplasm.